ir Omalizumab
Selected Abstract
FDA Issues Complete Response Letter for Xolair -- Omalizumab.
Business Editors/Health & Medical Writers SOUTH SAN FRANCISCO, Calif. & BASEL, SwitzerlandBW HealthWireJuly 10, 2001--Genentech, Inc. and Novartis AG today announced that they received a Complete Response letter from the US Food and Drug Administration (FDA) for their Biologics License ... July 10, 2001; Business Wire
Read the full article with a free-trial membership at HighBeam Research
Related Articles No Results Found.
|
